このエントリーをはてなブックマークに追加
ID 71217
FullText URL
Author
Hatano, Masakazu Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Hamano, Hirofumi Department of Pharmacy, Okayama University Hospital
Kanda, Masaya Department of Pharmacy, Asahikawa Medical University Hospital
Koseki, Takenao Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Nakai, Tsuyoshi Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Horii, Rina Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Yoshihara, Nozomi Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Saito, Takeo Department of Psychiatry, Fujita Health University School of Medicine
Takechi, Kenshi Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University
Esumi, Satoru The Faculty of Pharmaceutical Sciences, Kobe Gakuin University
Zamami, Yoshito Department of Pharmacy, Okayama University Hospital ORCID Kaken ID publons researchmap
Yamada, Shigeki Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
Abstract
Background: Clozapine is associated with a high risk of central nervous system abnormalities. However, seizure risk related to interactions between clozapine and other antipsychotics remains poorly characterized, and the pharmacological mechanisms underlying these seizures are unclear. Objectives: We aimed to evaluate safety signals for seizures associated with clozapine augmentation by other antipsychotics and analyze the relationship between these signals and neurotransmitter receptor occupancy profiles.
Design: A pharmacovigilance–pharmacodynamic analysis using a spontaneous reporting system.
Methods: This pharmacovigilance study used VigiBase, an adverse drug reaction database maintained by the World Health Organization. Drug–drug interactions (DDIs) between clozapine and other antipsychotics were assessed using the Ω shrinkage measure model. The association between DDI signals and neurotransmitter receptor occupancy was evaluated using linear regression. Robustness was tested using four frequency statistical models: additive, multiplicative, combination risk ratio, and chi-square statistic models. Results: Of 38,758,077 reports in VigiBase between 1990 and 2024, 230,371 involved clozapine. Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. A significant association between dopamine D4 receptor occupancy and the point estimates of signal values was observed in the Ω shrinkage measure model (β = 0.295, 95% confidence interval: 0.119–0.471, p = 0.002) and replicated across all frequency statistical models.
Conclusions: These findings suggest a potential role of dopamine D4 receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings.
Published Date
2026-07
Publication Title
Therapeutic Advances in Psychopharmacology
Volume
volume16
Publisher
SAGE Publications
ISSN
2045-1253
NCID
AA12610988
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© The Author(s), 2026.
File Version
publisher
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1177/20451253261472920
License
https://creativecommons.org/licenses/by-nc/4.0/
Citation
Hatano M, Hamano H, Kanda M, et al. Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261472920
助成情報
( 公益財団法人薬学研究奨励財団 / The Research Foundation for Pharmaceutical Sciences )
26K18918: 医療ビッグデータを用いた抗精神病薬副作用メカニズムの解明と薬理遺伝学に基づく検証 ( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )